Such cellular models are nevertheless very promising as they should help deciphering, in patient-derived neuromuscular preparations, the impact of Nav1.4 mutations on excitability and contractility of innervated myofibers and testing novel (bio)pharmacological strategies in Nav1.4 channelopathies. This evidence concerns the gene SCN4A and channelopathy.